Ovid Therapeutics President/CMO resigns; CEO added as President; new director appointed

Ovid Therapeutics Inc.

Dr. Amit Rakhit resigns as President and CMO effective Aug 27, 2021; will join Scientific & Clinical Advisory Board.
Resignation not due to disagreement with company on operations, policies, or financial matters.
CEO Jeremy M. Levin appointed President in addition to Chairman and CEO roles, effective upon Rakhit's departure.
Robert Michael Poole appointed Class I director effective July 9, 2021, term until 2024 annual meeting.
Poole entitled to standard non-employee director cash and equity compensation per company policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jeremy M. Levin

President

OVID · Ovid Therapeutics Inc.

Effective: 2021-08-27
Filed: July 8, 2021, 7:59 PM ET

the Company’s Board of Directors (the “Board”) appointed Dr. Jeremy M. Levin as President of the Company, in addition to his current duties as Chairman of the Board and Chief Executive Officer of the Company, effective upon the Officer Resignation.

Appointed

Robert Michael Poole

Class I director

OVID · Ovid Therapeutics Inc.

Effective: 2021-07-09
Filed: July 8, 2021, 7:59 PM ET

the Board appointed Dr. Robert Michael Poole as a Class I director of the Company, effective July 9, 2021

Departed

Dr. Amit Rakhit

President and Chief Medical Officer

OVID · Ovid Therapeutics Inc.

Effective: 2021-08-27
Successor: Jeremy M. Levin
Filed: July 8, 2021, 7:59 PM ET

Dr. Amit Rakhit, President and Chief Medical Officer of Ovid Therapeutics Inc. (the “Company”), notified the Company of his resignation from such positions with the Company effective August 27, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeremy M. Levin was appointed as President at Ovid Therapeutics Inc..

Action: appointed
Role: President

Exact text from the filing

the Company’s Board of Directors (the “Board”) appointed Dr. Jeremy M. Levin as President of the Company, in addition to his current duties as Chairman of the Board and Chief Executive Officer of the Company, effective upon the Officer Resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Michael Poole was appointed as Class I director at Ovid Therapeutics Inc..

Action: appointed
Role: Class I director

Exact text from the filing

the Board appointed Dr. Robert Michael Poole as a Class I director of the Company, effective July 9, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Amit Rakhit resigned as President and Chief Medical Officer at Ovid Therapeutics Inc..

Action: resigned
Role: President and Chief Medical Officer

Exact text from the filing

Dr. Amit Rakhit, President and Chief Medical Officer of Ovid Therapeutics Inc. (the “Company”), notified the Company of his resignation from such positions with the Company effective August 27, 2021

View on SEC.gov

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-036074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.